ArticleCureus2024
Two Cases of Remimazolam Anesthesia Managed With Pharmacokinetic Simulations in an Awake Craniotomy of Patients With Obesity.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Potential Advantages of Remimazolam for Awakening in Deep Brain Stimulation Surgery: A Retrospective Analysis of Cases.Journal of clinical medicine · 2025Article
- Clinical Experience With Remimazolam in Neuroanesthesiology and Neurocritical Care: An Educational Focused Review.Journal of clinical medicine research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anesthetic management for awake craniotomy (AC) often poses problems in patients with obesity including respiratory management. The Japan Awake Craniotomy Guidelines state that the indication for surgery should be carefully considered, especially in patients with obesity (body mass index (BMI) > 30). Patients with obesity often have comorbidities such as dyslipidemia, hypertension, and type 2 diabetes, and this is a risk factor for perioperative morbidity and mortality. Remimazolam, a new intravenous anesthetic, has been reported to be useful in anesthesia management during AC, but its use in obese patients has not been reported. Herein, we report two cases case series in which remimazolam was used in patients with obesity and safely managed under anesthesia with the pharmacokinetic simulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.